MannKind logo
MannKind
MNKD | NASDAQ
Chart Builder DCF Calculator
$3.96
-$0.17 (-4.12%)
At close: Nov 16, 2026, 4:00 PM ET
$3.96
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

MannKind Company Profile

Company profile explained

Company Profile

MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.

Key Executives

Name Position
Michael E. Castagna Chief Executive Officer & Director
Christopher Prentiss Chief Financial Officer
Ajay Ahuja Executive VP & Chief Medical Officer
David Thomson Executive Vice President, General Counsel & Secretary
Dominic Marasco President of Endocrine Business Unit
Sanjay Singh Executive Vice President of Technical Operations
Stuart A. Tross Chief People & Workplace Officer
Wassim Fares Senior VP and Therapeutic Area Head of Respiratory & (interim) Cariorenal

Latest SEC Filings

Date Type Title
Sep 28, 2026 4 Filing
Sep 14, 2026 4 Filing
Aug 21, 2026 8-K Current Report
Aug 21, 2026 424B7 Filing
Aug 14, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 10, 2026 4 Filing
Aug 05, 2026 10-Q Quarterly Report
Aug 05, 2026 8-K Current Report
Jul 31, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Jul 24, 2026 8-K Current Report
View All SEC Filings ➞
MannKind
MannKind logo
Country United States
IPO Date Jul 28, 2004
Industry Biotechnology
Sector Healthcare
Employees 592
CEO Michael E. Castagna

Contact Details

1 Casper Street Danbury, California 06810 United States

Stock Details

Ticker Symbol MNKD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000899460
CUSIP Number 56400P706
ISIN Number US56400P7069
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.